SUMMARYTwo methods have been developed for the introduction of deuterium into the doxepin molecule. The key intermediate (6,1l-dihydr0-1,2,3,4-~H,-dibenz b,e]oxepin-11-one, 5 ) was prepared by condensation of ethyl 2-bromomethylbenzoate with ['&&J-phenol, saponification of the resulting ester, and dehydration with trifluoroacetic anhydride. Using this key intermediate, E-( 1,2,3,4)-2H,-doxepin was repared for administration to human subjects.(1,2,3,4)-2H4-N-desrnethyldoxe in, (1,2,!,4,1',2',2')-21-17-doxepin, (1,2,3,4)-2H,-(N2H -doxepin (2H,o-doxepin) and (1,%3,4, 1',2',2')-2H,-N-desmethyldoxepin were also prepared q2 or use as internal standards in GC/MS assays. The deuterated compounds contained less than 0.5 % protiurn impurity.